Heart transplantation is the therapy of choice for end-stage heart failure. However, hemodynamic instability, which has been demonstrated in braindead donors (BDD), could also affect the posttransplant graft function. We tested the hypothesis that treatment of the BDD with the dopamine derivate noctanoyl-dopamine (NOD) improves donor cardiac and graft function after transplantation. Donor rats were given a continuous intravenous infusion of either NOD (0.882 mg/kg/h, BDD+NOD, n = 6) or a physiological saline vehicle (BDD, n = 9) for 5 h after the induction of brain death by inflation of a subdural balloon catheter. Controls were sham-operated (n = 9). In BDD, decreased left-ventricular contractility (ejection fraction; maximum rate of rise of leftventricular pressure; preload recruitable stroke work), relaxation (maximum rate of fall of left-ventricular pressure; Tau), and increased end-diastolic stiffness were significantly improved after the NOD treatment. Following the transplantation, the NOD-treatment of BDD improved impaired systolic function and ventricular relaxation. Additionally, after transplantation increased interleukin-6, tumor necrosis factor TNF-a, NF-kappaB-p65, and nuclear factor (NF)-kappaB-p105 gene expression, and increased caspase-3, TNF-a and NF-kappaB protein expression could be significantly downregulated by the NOD treatment compared to BDD. BDD postconditioning with NOD through downregulation of the pro-apoptotic factor caspase-3, proinflammatory cytokines, and NF-kappaB may protect the heart against the myocardial injuries associated with brain death and ischemia/reperfusion. Abbreviations: BD, brain death; BDD, brain-dead donors; DAPI, 4 0 ,6-diamidino-2-phenylindole; dP/ dt max , maximum rate of rise of left-ventricular pressure; dP/dt min , maximum rate of fall of left-ventricular pressure; EDPVR, slope of the end-diastolic pressurevolume relationship; ESPVR, end-systolic pressurevolume relationship; I/R, ischemia/reperfusion; LVEDP, left-ventricular end-diastolic pressure; LVESP, leftventricular end-systolic pressure; LV, left-ventricular; LVSP, left-ventricular systolic pressure; NF-KappaB, nuclear factor-kappaB; NOD, n-octanoyl-dopamine; PARP, poly(ADP-ribose) polymerase; PRSW, preload recruitable stroke work; ROS, reactive oxygen species; Tau, time constant of left-ventricular pressure decay; TNF-a, tumor necrosis factor a; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick endlabeling
Introduction
Cardiac transplantation still remains the "gold standard" surgical therapy for end-stage heart failure patients. Currently, the pool of heart donors is restricted to heartbeating brain-dead donors (BDD). However, brain death (BD) is associated with hormone depletion, severe hemodynamic changes, and a systemic inflammatory reaction (1, 2) , which in turn might affect the quality of donor heart allografts. Up to one fourth of potential BDD must be excluded due to hemodynamic deterioration or poor primary cardiac function (3) . Deterioration of organ quality before implantation, as well as myocardial ischemia/ reperfusion (I/R) injury at the time of transplantation, affect posttransplant graft responses (4, 5) and impairs short-and long-term graft function. The underlying mechanisms of BD include a systemic inflammatory reaction, with the generation of free radicals and expression of inflammatory cytokines (4) . The potential mechanisms of cold preservation injury include the secretion of proinflammatory mediators such as reactive oxygen species (ROS) (6) , cytokines and chemokines, and ATP depletion. Additionally, reperfusion of an ischemic myocardium is associated with further tissue damage, including intracellular "calcium overloading," energy depletion, an acidic environment, the activation of granulocytes, and the generation of ROS (7) . Under these circumstances, the I/R injury during cardiac transplantation may predispose the grafts from BDD to additional damage, such as a more intense inflammatory response, thus ultimately increasing the rate of acute graft rejection (8) .
There is an unmet need for new compounds, which might be considered for donor preconditioning, thus improving donor organ function before organ procurement and protecting allografts against hypothermic preservation/reperfusion injury. In a randomized multicenter trial, the pretreatment of BDD with low-dose dopamine has been associated with an improved heart allograft recipients' clinical course after transplantation (6) and with a decreased risk of postoperative right heart failure in pediatric heart recipients (9) . At low doses, dopamine receptors (DA 1 and DA 2 ) are activated, leading to vasodilatation in coronary vascular beds. It has also been demonstrated that dopamine detrimentally slows the amplification loop of intracellular calcium accumulation, and subsequently the cellular ATP consumption is decreased by the scavenging of ROS (10, 11) . The drawback, however, is that in BDD catecholamine accumulates, hence a low-dose dopamine treatment may result in tachycardia and/or hypertension in approximately 15% of the BDD (12) . As an alternative therapeutic approach, a synthetic dopamine derivate, n-octanoyl-dopamine (NOD), which belongs to the class of n-acyl dopamine derivatives, was developed, devoid of dopaminergic and adrenergic action, thereby lacking any hemodynamic effects. NOD shows superior effects compared to dopamine in terms of graft-protecting properties (13) and it mitigates cold preservation injury to cardiomyocytes (14) . Recently, recipients who received a heart from NODtreated BDD demonstrated lower plasma lactate dehydrogenase levels (15) . This lipophilic derivate NOD has structural similarities to the transient receptor potential channels of the vanilloid receptor subtype-1 agonist, capsaicin. The agonists of this receptor have the potential to prevent and attenuate I/R injury in different organs including the heart (16) . NOD therefore became an attractive candidate as a compound for donor organ conditioning prior to transplantation (17) .
Based on published in vitro and in vivo findings, we hypothesized that the treatment of BDD with NOD improves both donor and graft left-ventricular (LV) function in our well-established rat model of heterotopic heart transplantation (18) (19) (20) .
Materials and Methods

Animals
Male Lewis rats (250-350 g, Charles River, Sulzfeld, Germany) were housed in a room at 22 AE 2°C under 12-h light/dark cycles, and were fed a standard rodent regimen with water ad libitum. All animals received humane care in compliance with the "Principles of Laboratory Animal Care," formulated by the National Society for Medical Research, and with the "Guide for the Care and Use of Laboratory Animals" prepared by the Institute of Laboratory Animal Resources, published by the National Institutes of Health (NIH Publication No. 86-23, revised 1996). This study was reviewed and approved by the appropriate institutional review committees (G37/14).
Experimental groups
Rats were randomly assigned into three groups: (a) sham (n = 9): after the sham-operation, animals were given a continuous intravenous infusion of physiological saline NaCl 0.9% vehicle; (b) BD (n = 9): after the confirmation of BD, rats were given a continuous intravenous infusion of NaCl 0.9% vehicle; and (c) BD+NOD (n = 6): after the confirmation of BD, rats were given a continuous intravenous infusion of NOD (0.882 mg/kg/h). The application and dosage of NOD were determined according to reported data (15) . Figure 1 shows the experimental protocol. Five hours after the sham-operation or BD induction, donor hearts were perfused with a cold preservation solution (Custodiol), explanted, stored at 4°C in Custodiol, and heterotopically transplanted.
Sham-operated and BDD
Model of BD:
The rats were anesthetized with sodium pentobarbital (60 mg/kg, intraperitoneally), tracheotomized, endotracheally intubated, and ventilated by a rodent respirator as previously described (21) . A polyethylene catheter was inserted into the left external jugular vein for fluid administration. The body temperature (measured via a rectal probe) was maintained at 37°C. A 2F microtip pressure-volume catheter (SPR-838; Millar Instruments, Houston, TX) was inserted into the right carotid artery and advanced into the ascending aorta. A small 4F burr hole was drilled to the parietal skull, and a balloon catheter was introduced subdurally. BD was induced through a gradual increase of intracranial pressure, by slowly inflating the balloon with 15 lL saline per minute, until a total volume of 600 lL was reached. The state of BD was confirmed 40 min after the onset of BD, relying on the absence of corneal reflexes and a positive apnea test. The blood pressure was maintained via volume administration, without inotropic or vasoactive agents. Control donor rats were subjected to a sham-operation. Shamoperated and BDD were monitored for 5 h.
LV cardiac function before and 5 h after sham-operation or BD induction: Hemodynamic measurements were performed at a baseline condition (before BD induction) and 5 h after the sham-operation or BD induction (T = 5 h). To assess the cardiac function, the 2F pressure-volume conductance catheter (Millar Instruments) was advanced into the left ventricle under pressure control, as previously described (22) . With the use of a special pressure-volume analysis program (PVAN, Millar Instruments), heart rate, mean arterial pressure, LV end-systolic pressure (LVESP), LV end-diastolic pressure (LVEDP), maximum rate of rise of LV pressure (dP/dt max ), maximum rate of fall of LV pressure (dP/dt min ), and ejection fraction were calculated. Ventricular relaxation was assessed by the time constant of LV pressure decay (Tau). LV pressure-volume relations were measured by transiently occluding the inferior vena cava (reducing preload) under the diaphragm with a cotton-tipped applicator. The slope E max (according to the parabolic curvilinear model (23)) of the end-systolic pressure-volume relationship (ESPVR), and preload recruitable stroke work (PRSW) were calculated as load-independent indexes of LV contractility. The slope of the enddiastolic pressure-volume relationship (EDPVR) was calculated as a reliable index of LV stiffness. Additionally, arterial elastance (Ea) was calculated, and ventriculo-arterial coupling was described by the quotient of ESPVR and Ea (24) .
Biochemical analysis of sham-operated and BDD: After the hemodynamic measurements were completed, blood samples from the abdominal aorta were collected in a Lithium-Heparin-Gel Monovette â (Sarstedt AG & Co, N€ umbrecht, Germany). Then, after centrifugation (4500g, 15 min, 4°C), plasma samples were obtained. Levels of creatine kinase MB isoenzyme and high-sensitive cardiac troponin-T were determined using standard automated clinical assays. The levels of tumor necrosis factor (TNF)-a were measured via Rat TNF-a Quantikine ELISA kit (R&D Systems, Inc., Minneapolis, MN).
Model of heterotopic heart transplantation
Surgical technique of heart transplantation: Transplantations were performed in an isogenic Lewis-to-Lewis rat strain model. The experimental model was described elsewhere (18) (19) (20) . Briefly, 5 h after BD or sham-operation the donors were heparinized (400 IU/kg). Cardiac arrest was induced with Custodiol solution (histidine-tryptophanketoglutarate; Dr. Franz K€ ohler, Chemie GmbH, Bensheim, Germany), then the superior and inferior caval veins and the pulmonary veins were tied en masse with a 4-0 single silk suture. Then, the heart was immediately placed into Custodiol solution (4°C).
Recipient rats were anesthetized with a single intraperitoneal injection of xylazine (3 mg/kg) and ketamine (100 mg/kg), and they were heparinized (400 IU/kg). The aorta and the pulmonary artery of the donor heart were anastomosed end to side to the abdominal aorta and the vena cava of the recipient rat, respectively. To minimize variability between experiments, the duration between explantation and reperfusion was standardized to 1 h. After completing the anastomoses, the heart was reperfused with blood in situ for 1.5 h.
Functional measurement in the graft: One and a half hours after transplantation, a 3F latex balloon catheter (Edwards Lifesciences Corporation, Irvine, CA) was introduced into the left ventricle via the apex. LV systolic pressure (LVSP), Tau, dP/dt max , and dP/dt min were measured by a Millar micromanometer (Millar Instruments) at different LV volumes. From these data, LV pressure-volume relationships were constructed using the PVAN 3.6 software (Millar Instruments).
Histology and immunohistochemistry in the graft: Following the functional measurements, the hearts were explanted, and pieces of myocardial tissue were immediately fixed in buffered paraformaldehyde solution (4%) and embedded in paraffin. Five-micron-thick sections were stained with hematoxylin and eosin. The degree of inflammation and necrosis were evaluated by scoring according to the grades 0-3, under a light microscope with nine sections from each sample. Immunohistochemistry for myeloperoxidase (1:200; Abcam, Cambridge, UK) (determination of neutrophils accumulation) and for CD68 (1:200; Dako, Glostrup, Denmark) (identification of macrophages) were performed and the evaluation was done in four randomized nonoverlapping fields of the myocardium, and an average value was calculated.
Detection of DNA strand breaks in the graft: We performed terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) staining to detect DNA-strand breaks as previously described Figure 1 : Experimental protocols. Left-ventricular cardiac function was measured 5 h after sham operation or confirmation of brain death. Either a saline vehicle (sham-and BD groups) or NOD (BD + NOD group) were administered via continuous intravenous infusion for 5 h. Then the hearts were explanted, stored (1 h ischemia) at 4°C in a cold preservation solution (Custodiol), heterotopically transplanted, and perfused with blood in situ (1.5 h reperfusion). Posttransplant graft function was evaluated, and samples were collected for further analysis. BD, brain death; NOD, n-octanoyl dopamine. Chemical reagents preparation and application NOD was provided by Novaliq GmbH (Heidelberg, Germany). It was prepared in 2 mL NaCl 0.9% vehicle, and administered intravenously at a dose of 0.882 mg/kg/h for 5 h after BD induction.
Statistical analysis
All data are expressed as meanAEstandard error of the mean. Intergroup comparisons were performed by using a one-way analysis of variance, followed by a Student's unpaired t-test with Bonferroni's correction for multiple comparisons. A value of p < 0.05 was considered indicative of significance.
Results
Effects of NOD on the donors NOD treatment improves LV cardiac function of BDD: Five hours after BD induction, heart rate, systolic and diastolic blood pressures, and mean arterial pressure were significantly lower in the BDD when compared to the sham group (Table 2) . BD was associated with a significant decrease of load-dependent parameters (decreased ejection fraction, LVESP, dP/dt max ) and loadindependent indexes (the slope E max of the end systolic pressure-volume relationship, PRSW [the slope of the linear relationship between stroke work and end-diastolic volume]) compared to sham group (Table 2 and Figures 2A-C) . Additionally, LV afterload (Ea) showed a tendency to decrease (without reaching a significance difference) in the BD group, whereas the ventriculoarterial coupling ratio remained constant among the groups (Table 2 ). However, after NOD treatment, Ea remained decreased and ESPVRq was significantly increased; therefore, the ventriculo-arterial coupling ratio was significantly improved. Furthermore, the treatment of BDD with NOD significantly increased systolic performance. Impaired LV active relaxation (decreased dP/ dt min and prolonged Tau), increased LV diastolic stiffness (an increase the slope of the EDPVR), and impaired LV preload (LVEDP values were used for estimating LV preload) after BD were significantly improved by the NOD treatment (Table 2 and Figures 2D-F) . Donors' heart rate values did not differ significantly between BD and BD+NOD groups ( Table 2 ).
Biochemical parameters: Five hours after BD induction, TNF-a could not be detected in the plasma of both sham-operated and BD+NOD donors (<5 pg/mL), whereas in the BDD its concentration reached 425 AE 15 pg/mL. Additionally, creatine kinase MB and circulating cardiac high-sensitive troponin T concentrations, indicating myocardial injury, were significantly elevated in BDD compared to the sham GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NFkB p65, nuclear factor B p65 subunit; NFkB p105, nuclear factor B p105 subunit. group. However, the treatment with NOD has no effect on these parameters (Table 3) .
NOD treatment reduces graft injury associated with BD and heart transplantation LV function of the graft: After heart transplantation, significantly decreased LVSP, developed pressure, and dP/dt max were observed in the BDD hearts when compared with the sham-operated group, indicating a decreased systolic function ( Figures 3A-C) . Furthermore, the rate pressure product, used to determine the myocardial workload, was significantly decreased in the BD group compared to sham-operated animals (Figure 3D) . Moreover, diastolic dysfunction was observed in the BD heart, as reflected by decreased dP/dt min and a prolonged Tau ( Figures 3E and F) . The treatment of BDD with NOD significantly improved LV graft systolic and diastolic function. Additionally, after transplantation, there was no significant difference in the heart rate among the groups (sham 185 AE 6 vs. BD 149 AE 11 vs. BD+NOD 186 AE 17 beats/min, p > 0.05).
Histological and immunohistochemical evaluation of the graft: After transplantation, a semiquantitative histological evaluation of hematoxylin and eosin-stained myocardial tissue revealed an increased inflammatory cell infiltration and necrosis in the BDD hearts when compared with the control group, which were, in turn, decreased by the NOD treatment ( Figures 4A and B) .
Additionally, after transplantation, the number of myeloperoxidase-expressing cells was significantly higher in the BD hearts than in the sham-operated donor hearts. The treatment of BDD with NOD showed a tendency toward a decreased neutrophil infiltration compared to the vehicle-treated BD group, without reaching statistical significance ( Figures 4A-C) . However, while the number of CD68-positive cells was similar among the groups, a tendency toward increased CD68+ cells in the graft from BDD compared to the sham and BD+NOD groups could be observed (Figures 4A-D) .
DNA strand breaks and protein expression of the graft: The density of TUNEL-positive nuclei was significantly increased in the myocardium after transplantation, indicating DNA fragmentation. The treatment of BDD with NOD significantly decreased DNA strand breaks after heart transplantation ( Figures 5A-D) . The densitometric analysis of bands for caspase-3 showed a significant increase in the BD hearts compared to shamoperated donor hearts; a decrease could be seen following the NOD treatment ( Figure 5E ). Furthermore, after transplantation, PARP-1 expression showed a tendency to increase in the BD hearts compared to sham-operated donor hearts, and a tendency to decrease in the BD+NOD group was seen ( Figure 5F ).
Expression of genes and proteins involved in the inflammatory response in the graft: After transplantation, myocardial IL-6 and TNF-a mRNA expression were significantly upregulated, and gene expression of NFkB p65 and NFkB p105 showed a tendency to increase (without reaching a significant difference) in the BD hearts compared to sham-operated donor hearts. The treatment of BDD with NOD significantly downregulated all these tested genes ( Figures 6A-D) . Furthermore, the densitometric analysis of bands for TNF-a and NF-KappaB showed a significant increase in the BD hearts compared to the shamoperated donor hearts. This increase was prevented by the NOD treatment ( Figures 6E and F) .
Discussion
In the present study, we investigated whether the dopamine derivate NOD would have beneficial effects on both BDD cardiac and graft functions in a rat heart transplantation model. We have shown that the treatment of BDD with NOD resulted in the functional recovery of grafts after cardioplegic arrest, hypothermic storage, transplantation, and blood reperfusion. A postconditioning of BDD with NOD would protect the heart against the myocardial injuries associated with BD and I/R via downregulation of the pro-apoptotic factor caspase-3, pro-inflammatory cytokines, and NF-kappaB.
Effects of NOD treatment on cardiac dysfunction after BD Using an in vivo experimental model, we studied the cardioprotective effect of NOD when administered after the onset of BD, to simulate a clinical situation. Experimental BD models, with a sudden increase in intracranial pressure, lead to a severe impairment of myocardial function and hemodynamic performance (19, 26) . In line with these observations, in the present study, we demonstrated that BD causes severe hemodynamic deterioration. Additionally, the relationship between the slope of the ESPVRq and Ea (ESPVR/Ea) reflects the mechanical coupling between left ventricle and arterial circulation. In accordance with the literature (27) , LV afterload decreased 5 h after BD. The main explanation of decreased afterload after BD is the loss of sympathetic tone, which was previously described in detail (1, 3, 26, 27) . Similar to previous studies, myocardial contractility (ESPVRq) significantly decreased after BD (19, 21) . In agreement with the literature (27), these observations indicate that reduced myocardial contractility after BD is related, at least partially, to reduced afterload. Thereby, ventriculo-arterial coupling and mechanical efficiency remained unchanged in the BDD. The treatment with NOD led to a preserved contractile function. In the context of reduced afterload this leads to an improvement of the ventriculo-arterial coupling ratio. Here, with the use of in vivo cardiac catheterization and LV pressure-volume analysis, we showed that BD was characterized by a decreased systolic performance (decreased dP/dt max , E max , and PRSW), accompanied by impaired LV active relaxation (decreased dP/dt min and prolonged Tau), altered diastolic stiffness (increased EDPVR), and an impaired LV preload (increased LVEDP). We found that the administration of NOD after the onset of BD was capable of improving BDassociated LV systolic and diastolic dysfunction.
Effects of NOD treatment on graft dysfunction associated with BD and heart transplantation The alterations in graft cardiac function may provide significant prognostic data about the clinical outcome after heart transplantation. Our results demonstrated that after hypothermic storage and subsequent reperfusion of the BD hearts, such as occurs before and during cardiac transplantation, myocardial contractility (shown by decreased dP/dt max , developed pressure, and rate pressure product) and the active phase of the relaxation index (as reflected by reduced dP/dt min and prolonged Tau) were impaired in recipients. Thus, cardiac injury induced by BD may be aggravated by hypothermic preservation/ reperfusion, and it may contribute to a reduced ischemic tolerance (19) . Additionally, our results strongly suggested that conditioning with NOD after the onset of BD in BDD could improve the outcomes of heart transplantation in rats. Furthermore, heart rate values were similar between BD and BD+NOD groups in donors before and after transplantation. These observations were also supported by Spindler et al, showing no statistically significant influence of NOD on heart rates between the groups, when the donor heart rate was evaluated 2 h after the induction of BD for a 1-min interval (15) . Altogether, we have shown that donor postconditioning with a dopamine derivate NOD promoted the preservation of graft LV contractility and relaxation after transplantation. Despite this, the results from animal studies should be extrapolated to human cases with caution. These novel results have potential consequences in cardiac transplantation.
Mechanisms of cardioprotective effects of NOD against BD-and I/R-induced injuries
The precise molecular mechanism of the synthetic dopamine derivate NOD, which is devoid of hemodynamic action, is not yet fully elucidated. NOD has a profound anti-inflammatory character by inhibiting TNF-amediated inflammation through a downregulation of pro-inflammatory chemokines and cellular adhesion molecule expression (28) . NOD is also a potent inhibitor of platelet function, most likely through intracellular redoxactive processes (17) . Furthermore, it has been suggested that the antioxidant properties of NOD could be responsible for its protective effects. In the present study, the potential molecular mechanisms underlying the cardioprotective effects of NOD against BDassociated cardiac dysfunction and I/R injury during heart transplantation were investigated. Our data suggest that NOD mediated cardioprotection by downregulating apoptotic and inflammatory protein expression. The activation of caspase-3 leads to downstream cleavage of various nuclear substrates including PARP. These two main components can lead to cell death via apoptosis. In the present work, after heart transplantation, BDD treated with NOD showed a significant downregulation of increased caspase-3, and a tendency toward a decreased PARP-1 protein expression compared to untreated BDD, suggesting a decrease of apoptosis. This thesis was confirmed by our TUNEL staining, showing DNA fragmentation, one of the last phases in apoptosis. Additionally, the transcription factor NF-KappaB functions as an important regulator of cardiac gene expression associated with ischemia and reoxygenation of hypoxic tissue during reperfusion (29) . It is activated by pro-inflammatory cytokines such as IL-1 and TNF-a, as well as via induction of ROS, leading to inflammatory processes (28) . It has been demonstrated that NOD inhibits the expression of NF-KappaB-regulated genes, and may thus cause a decreased pro-inflammatory cytokine production, including TNF-a (29) . In line with these observations, our results showed an upregulation of NF-KappaB and TNF-a genes and proteins and overexpression of the IL-6 gene in hearts derived from BDD after transplantation, which was inhibited by NOD postconditioning, suggesting a reduced TNF-a-mediated inflammation. Additionally, before organ preservation, plasma TNF-a concentrations were higher in BDD than in sham-operated donors, and after NOD treatment its concentration could not be detected in BDD. These findings were confirmed by histological assessments, revealing significantly decreased inflammation (evidenced by hematoxylin and eosin staining) and lower levels of neutrophil infiltration (evidenced by the myeloperoxidase staining) after the NOD treatment in cardiac grafts from BDD posttransplantation.
Some limitations need to be addressed. Firstly, the prolonged anesthesia in this experimental model of BD could affect the donors' cardiac function. Secondly, the rat model of cardiac transplantation is a suitable model to evaluate global I/R injury. However, the heart is perfused via the coronary circulation and the left ventricle is beating in an unloaded condition; therefore it does not eject, which on the one hand allows a faster recovery after I/R, and on the other hand leads to time-dependent mechanical deterioration and atrophy. Nevertheless, detailed characterization studies have shown that major deterioration does not occur until at least 24 h after implantation (30) . Thirdly, in this model, the assessment of long-term effects of reperfusion after transplantation will give rise to a lot of profound functional, structural, and metabolic changes. However, early graft dysfunction is the main determinant of the long-term outcome following transplantation. Therefore, the evaluation of graft function during the early phase post-heart transplantation has clinical significance and importance. Finally, we did not assess right ventricular structure and function, but confined the investigation solely to the left ventricle.
Conclusions
The data reported in this in vivo study provide experimental evidence that the downregulation of the main downstream effector of apoptosis caspase-3, proinflammatory cytokines TNF-a and IL-6, and NF-kappaB could underlie the protective effect of NOD against myocardial injuries associated with BD and I/R. NOD might be a novel therapeutic approach to reduce cumulative myocardial injuries related to BD and heart transplantation. Further studies are required to reveal additional mechanisms underlying NOD's protective effects in transplanted hearts.
